NFKB1 and cancer: Although the proteasome inhibitor bortezomib can target the constitutive NF-κB activity maintained by both canonical and non-canonical pathways, proteasome inhibitor resistant mechanisms of NF-κB activation have been identified and one of them in particular, the PIR pathway, is constitutively activated in several cancer cell lines [43-46,56-58].